REVIEW

Immunological Basis of Melanoma-Associated Vitiligo-Like Depigmentation

R. González, a,∗ E. Torres-López b

a Departamento de Introducción a la Clínica, Facultad de Medicina, Universidad Autónoma de Nuevo León, Nuevo León, Mexico
b Departamento de Inmunología, Hospital Universitario Dr. José Eleuterio González, Monterrey, N.L. México, Col. Mitras Centro, Monterrey, Nuevo León, Mexico

Received 16 March 2012; accepted 20 June 2012
Available online 25 February 2014

Abstract Vitiligo is a skin condition characterized by white, hypopigmented macules. Melanocyte loss is a feature of the disease, and it has been hypothesized that an autoimmune mechanism could be responsible for the depigmentation. Melanoma is a malignancy that develops in melanocytes; if not detected and treated early, it is often deadly. Leukoderma, a condition characterized by depigmentation of the skin, is sometimes associated with malignant melanoma. An immune response against melanocyte antigens leading to destruction of either melanoma cells or melanocytes has been observed in both vitiligo and melanoma. Studies in animal models and humans have shown that humoral and cell-mediated immune responses are involved in modulating cytotoxic activity against tumor cells and normal melanocytes. The study of factors associated with anti-tumor immunopathogenic mechanisms—autoimmunity for example—may provide us with tools for the diagnosis and treatment of diseases such as vitiligo and malignant melanoma.

© 2012 Elsevier España, S.L. and AEDV. All rights reserved.

KEYWORDS
Melanoma; Vitiligo; Leukoderma; Autoimmunity

PALABRAS CLAVE
Melanoma; Vitiligo; Leucodermia; Autoinmunidad

Bases inmunológicas de la hipopigmentación vitiligoide asociada a melanoma

Resumen El vitíligo es una patología cutánea que se manifiesta en forma de manchas hipocromáticas y acrómicas. Se caracteriza por la pérdida de melanocitos y se ha hipotetizado que un mecanismo autoinmunológico podría estar estrechamente relacionado con este fenómeno de despigmentación. El melanoma es una neoplasia maligna derivada de los melanocitos, que es letal si no se trata oportunamente. La leucodermia es un fenómeno de despigmentación cutánea, que ocasionalmente se puede asociar a melanoma. Tanto en los pacientes con vitíligo como con melanoma se ha observado una respuesta inmune contra antígenos de las células melanocíticas, ya sea para la destrucción de los melanocitos normales como de las células tumorales. A través de diversos estudios en humanos y modelos animales se ha observado que,

Please cite this article as: González R, Torres-López E. Bases inmunológicas de la hipopigmentación vitiligoide asociada a melanoma. Actas Dermosifiliogr. 2014;105:122–127.

* Corresponding author.
E-mail address: roger.gonzalez@onderm.com.mx (R. González).

1578-2190/$ - see front matter © 2012 Elsevier España, S.L. and AEDV. All rights reserved.
**Introduction**

Vitíligo es un trastorno caracterizado por áreas blancas, depigmentadas que no contienen melanocitos. El cuadro se puede presentar de manera congénita o familiar, y en el mundo, la prevalencia general es estimada en 0.5% y la incidencia es aproximadamente 1% al 2% en la población total. Clínicamente, vitíligo se presenta con cuadros de pigmentación pálida. Los patrones de depigmentación vitíligo incluyen lesiones focales vitíligo (islas de melanocitos), vitíligo segmental (una lesión unilateral de melanocitos que afecta la piel) y vitíligo universalis (un área de depigmentación en toda la piel y el cuerpo). Vitíligo universalis (frecuentemente en la piel y el cuerpo) es un trastorno que afecta más del 80% de la superficie corporal.

Determinadas proteínas localizadas en melanomas son necesarias para la síntesis de melanina, el pigmento responsable de la coloración de los ojos y la piel. Estas proteínas incluyen melanomas y melanocitos y se derivan de dos grupos:

- Tyrosinase y tyrosinase asociada proteína 1 (encoded por el TYRP-1 gen) y proteína 2 (encoded por el TYRP-2 gen), que catalizan los pasos bioquímicos en la síntesis de melanina.
- Melanoma-antígeno reconocido por células T (MART-1), Pmel17, Rab7, y Rab27, responsable de la retención de melanocósitos y transporte de melanina y melanina, entre otros.

El tratamiento vitíligo puede depender de la presencia y severidad de comorbilidades asociadas. El tratamiento se basa en agentes inmunosupresores (corticosteroides y calcineurinas) y fototerapia para inducir repigmentación. En casos de extensa depigmentación, la repigmentación de la piel se puede llevar a cabo mediante el uso de hidroquinona.

Melanoma es un neoplasm mucocutáneo o ocular que puede ser sporádico o familiar. El neoplasm está asociado con una variedad de factores genéticos. Otros factores predisponentes incluyen exposición a luz solar intensa, fotoescalado (Fitzpatrick's skin type I y II) y fotoperiodismo (regresión), aunque algunos pacientes con fotoperiodismo pueden presentar melanoma. Melanoma afecta alrededor del 5% de todos los cánceres, con una incidencia de 2% en hombres y mujeres en cada grupo de edad. El tratamiento de melanoma entre caucásicos se ha reportado que aumenta de manera significativa de 3% a 7% cada año.

El tratamiento clínico de melanoma se ha publicado en dermatología y otras disciplinas, y el presente documento no cubre en detalle todos estos temas. Es importante que los profesionales de la salud sean capaces de identificar y tratar adecuadamente estas condiciones.

El melanoma es un trastorno de pigmentación que puede afectar cualquier zona del cuerpo. El melanoma se clasifica en diversas formas según su severidad, y se tratan de diversas maneras. Los tratamientos incluyen cirugía, radiación, quimioterapia, inmunoterapia y terapia génica.

Materiales y métodos: Se realizó un estudio retrospectivo de pacientes con vitíligo y melanoma. Se recopilaron datos demográficos, clínicos y tratamientos recibidos. Se buscó correlacionar la presencia de vitíligo con la incidencia de melanoma.

**Conclusión**

La inmunidad humoral y celular desempeñan un papel en la citotoxicidad contra el melanoma. El estudio de los factores asociados a la inmunidad humoral y celular puede mejorar la comprensión del papel de la inmunidad en la protección contra el melanoma. La detección temprana y el tratamiento adecuado son fundamentales para mejorar la supervivencia de estos pacientes.
Cancer/testicular antigens. These antigens are highly expressed in normal tissue during development, while expression is limited to testicles and the placenta in adults. They are expressed in some types of cancer. This group includes the melanoma antigen family (MAGE), B antigen family (BAGE), G antigen family (GAGE), and New York esophagus (NY-ESO-1).

Differentiation Antigens. These antigens are expressed by both tumor cells and their normal counterparts, but not in other cell types. In turn, this group of antigens is divided into 2 groups. The first group includes melanosomal membrane proteins such as TYRP-1, TYRP-2, Pmel17 (also known as gp100), and MART-1. Gangliosides (GDs) form the second group. These are widely present in melanoma cells and are thought to play a role in cell-cell and cell-matrix adhesion and in growth factor binding, suggesting that they may be involved in the invasive process of the tumor. This group includes GD3, GD2, GM2, GM3, and O-acetyld GD3.

Melanoma therapy depends on the clinical stage. In early stages, treatment is mainly surgical. Interferon alfa (IFNα) has been used primarily as adjuvant therapy in patients with melanoma who are disease-free after appropriate surgery, but with an intermediate or high risk of recurrence. For advanced stages (disseminated melanoma or inoperable locoregional disease), chemotherapy, radiotherapy, and chemoimmunotherapy have been used with agents such as interleukin 2 (IL-2), which enhances the cytotoxicity of antigen-specific T and natural killer (NK) cells in vitro. The response rates, although less than 20%, are nevertheless promising. Currently, new treatments against therapeutic targets such as KIT or BRAF are emerging. Another agent that forms part of this generation, the so-called targeted therapy, is the monoclonal antibody denominated ipilimumab (anti-CTLA4). Effort has also been made to develop immunotherapy regimens with dendritic cells, whether in monotherapy or enhanced with molecules such as the glycoprotein gp100, and methods such as lymphocyte transfer. The above approaches reflect the strong interest in melanoma research.

Melanoma-Associated Leukoderma

In certain circumstances, vitiligo (leukoderma) may develop in patients with malignant melanoma, mainly in advanced stages. The relationship between melanoma and leukoderma is a controversial and fascinating topic. Around 3% of patients with melanoma may present this melanoma-associated vitiliginous depigmentation. Hypopigmentation (leukoderma) in association with benign and malignant melanocytic lesions has been reported frequently with different clinical forms which include regression lesions adjacent to primary melanomas or their metastases (Fig. 1), nevus with halo (Sutton) around preexisting melanocytic nevi, and vitiliginous lesions at sites distant to the melanoma, whether isolated or associated with ocular findings of the Vogt-Koyanagi-Harada syndrome.

Distant leukoderma may present during the course of melanoma, particularly in cases of advanced stages (metastasis) and the corresponding therapies (mainly immunotherapy-based treatments with IL-2 or IFNα/β).

Longer survival has been observed in patients who develop leukoderma associated with melanoma in advanced stages compared to patients with advanced melanoma who do not develop it, suggesting that this is a reflection of the presence of an antitumor activity in the patient. This melanoma-associated phenomenon presents with a frequency of between 1.4% and 20%. Unfortunately, as mentioned earlier, the efficacy of this antitumor response is not sufficiently great to increase the chance of complete eradication of melanoma.

Clinically, melanoma-associated leukoderma bears certain similarities with vitiligo. The prevalence of vitiligo among melanoma patients is estimated to be between 3% and 6%. In a series of 15 patients with melanoma and hypopigmentation, leukoderma was found to be directly associated with melanoma in 12 cases (80%). Hypopigmentation was observed on average 4.8 years after initial diagnosis of melanoma, and the age of onset was found to be 56.4 (10.8) years, in comparison with the age in a group of nonmelanoma associated vitiligo of 27.6 (16.5) years. There was no difference between sexes in the frequency of the association. In that series of cases, 75% of the patients with melanoma-associated leukoderma had a bilateral and symmetrical distribution of depigmentation similar to disseminated vitiligo, whereas only 25% of the population studied had a focal or asymmetric unilateral distribution of hypopigmentation; no patients with the association had an acrofacial distribution of depigmentation. The progression of melanoma-associated leukoderma is not as fast or progressive as is usually the case with depigmentation in vitiligo. There is no histologic or immunohistochemical difference between the 2 forms of depigmentation. Observations that differentiate between melanoma-associated leukoderma and vitiligo include family history of vitiligo, partial decoloration, and extensive patchy distribution. There is no sufficiently solid evidence to suggest that patients with melanoma are at greater risk of developing vitiligo or vice versa. Therefore, given the low frequency of the phenomenon, once diagnosis of cutaneous, mucosal, or ocular melanoma has been made, no special follow-up
or greater vigilance is required to detect leukoderma. An appropriate physical examination is sufficient to assess whether hypopigmented lesions are present or not.

The association between leukoderma and melanoma is probably the result of a dual immune response against antigens present in both melanocytes and melanoma cells,\(^{1,4}\) where the primary immunologic effect would be tumor rejection, but with a simultaneous secondary autoimmune effect characterized by hypopigmented macules (leukoderma).\(^{8}\)

**Role of Humoral Immunity in Melanoma-Associated Leukoderma**

The autoimmune (and even antitumor) effects are largely mediated by antibodies against melanocytic differentiation antigens (tyrosinase, TYRP1, TYRP2, and Pmel17). For example, Merimsky et al.\(^{22}\) found significantly higher levels of antityrosinase antibodies in the serum of patients with vitiligo compared to patients with metastatic melanoma, melanoma-associated leukoderma, and healthy controls. They also observed an in vitro inhibition of the proliferation of melanoma cells and a decrease in the incidence and number of metastases in animal models in which animals were treated with immunoglobulin (Ig) G from patients with vitiligo. High titers of anti-TYRP2 IgG antibodies have been found in patients with vitiligo, a similar phenomenon to that observed in patients with melanoma and immunotherapy-induced depigmentation.\(^{1}\) Antibodies against the Pmel17 antigen were also detected in a population of patients with vitiligo using radioimmunoassay.\(^{23}\) In contrast, autoantibodies have not been found in patients with vitiligo.\(^{1}\) Further evidence that humoral immunity and melanoma-associated leukoderma play an important role is the finding that the murine monoclonal antibody TA99 (IgG2a) against the TYRP1/Tygp75 protein is associated with hypopigmentation in murine models with melanoma (B16 lineage).\(^{8}\)

Although depigmentation can be considered a cosmetic issue, it is interesting to highlight that the immunologic threshold for depigmentation has been shown to be significantly higher than that required for tumor rejection. This is because antibodies can more readily access solid tumors, which have their own vascularization, than melanocytes, which are located in the basal membrane of the epidermis and follicular epithelia.\(^{1}\)

In the study conducted by Boasberg et al.\(^{24}\) in a group of 49 patients with metastatic melanoma who were treated initially with concurrent biochemotherapy (dacarbazine, cisplatinum, vinblastine, IL-2, and IFNα2b) and then with maintenance biotherapy based on IL-2 and granulocyte and monocyte colony stimulating factor (GM-CSF), 21 patients (43%) developed vitiligious lesions. Survival in this subgroup of patients was close to 18.2 months compared to 8.5 months in patients who did not develop leukoderma. High titers of anti-TYRP2 IgG were found in the group of patients with leukoderma (6 out of 21 patients, 29%) compared to patients without depigmentation (4 out of 28 patients, 14%). There were no statistically significant differences in the titers of anti-gp100 antibodies between the subgroups of patients.

**Role of Cellular Immunity in Melanoma-Associated Leukoderma**

As mentioned earlier, vitiligo lesions contain an inflammatory infiltrate composed of macrophages, dendritic cells, and T lymphocytes, mainly of the CD8+ subpopulation,\(^{25}\) although CD4+ cells have also been detected. In peripheral blood of patients with progressive vitiligo, as well as in patients with melanoma (after concurrent development of depigmentation), CD8+ T cells reactive against MART-1 have been detected. In a similar population, it was found that more than 15% of the T cells in peripheral blood were reactive to the 209-217 epitope of the gp100 antigen. These 2 antigens are considered the most immunogenic of melanocytes. Moreover, T cells that infiltrate melanoma tumors are very reactive against these 2 proteins.\(^{3}\)

Ramírez-Montagut et al.\(^{8}\) found that T cells specific for the Melan-A/MART-1 protein were present in 50% of a population of patients with melanoma although there was no correlation with better prognosis. Another study showed the presence of CD8+ cells specific for melanocytes in peripheral blood in patients with melanoma, as well as in patients with vitiligo.\(^{26}\) Specifically, these cells were reactive against tyrosinase and Melan-A/MART1 in these groups of patients and most expressed HLA-A*0201.\(^{26}\) The specificity of epitopes that are targeted by CD8+ cells suggests that the cells responsible for tumor reduction also cause depigmentation.

In a transgenic melanoma mouse model, almost half the animals (45 out of 88) had permanent leukoderma. In follow-up at 6 months of age, the animals with melanoma-associated leukoderma had significantly fewer facial and dorsal tumors than animals of the same age that had not developed leukoderma. This study also showed that the proportion of peripheral blood lymphocytes specific for melanoma was significantly greater in the subgroup of mice with melanoma-associated leukoderma (1 out of every 680 lymphocytes) than in mice without leukoderma (1 out of every 1000 lymphocytes). These lymphocytes were predominantly CD8+ and they also induced secretion of IL-12 and IFN-γ, both of which possess antitumor properties.\(^{27}\) The infiltration of immune cells confers a certain degree of protection in this model, as 140 days after the introduction of Melan-ret syngeneic cells, 25% of the transgenic mice with vitiligo were still protected against melanoma, whereas no leukoderma-free mice were protected. The antitumor reactivity is mediated by CD8+ cells specific for TYRP2 and gp100. The same authors have shown the natural induction of cellular immunity mediated by CD8+ T cells in humans during the course of melanoma progression and development of leukoderma.\(^{27}\)

It is still subject of debate whether the presence of CD8+ T cells is the cause or a consequence of leukoderma, as reflected in a study by Byrne et al.\(^{28}\) in which the autoimmune destruction of melanocytes was shown to be necessary for an appropriate and lasting antitumor immune response in a mouse model.

The role of IL-2 is crucial in the development of antitumor cellular immune responses because, in addition to inducing the recruitment of cytotoxic and NK T cells, this cytokine has also been observed to suppress CD4+CD25hiFoxP3+ regulatory T cells (regulatory T cells
that are the first antigen-specific T suppressor cells) in patients with metastatic melanoma who respond favorably to the cytokine. Therefore, IL-2 increases cytotoxic function in CD8+ cells responsible for both tumor regression and autoimmunity.7

**Perspectives**

Animal models such as the Sinclair pig are very valuable for understanding the pathogenesis of melanoma-associated entities. This species is born with congenital melanomas that spontaneously regress a few weeks after birth with the concurrent presentation of generalized hypopigmented macules. An increase was observed in the titers of antibodies against pigmented cells on presentation of leukoderma.2

The B16 melanoma cell line has been used in mice models to continue the line of investigation into humoral response against antigens of melanocyte differentiation, and it has even been observed that passive immunization with antibodies against TYRP-1/gp75 results in rejection of the syngeneic melanoma and reduction in pulmonary metastases in animal models of metastatic melanoma.9

Lengagne et al.25 established an experimental model in MT/ret transgenic mice with the B6 cell line. The animals in this model develop melanoma lesions at an early age (65% of mice in a 10-month period) and, subsequently, vitiliginous lesions. The authors suggested that the addition of zinc to the water of the mice had induced the development of melanoma.

Cytotoxic T-cell associated antigen 4 (CTLA-4) is responsible for negative regulation of the activated cytotoxic T cells. Blockade of this molecule with a specific anti-CTLA-4 antibody has been demonstrated both in animal models and in humans, with favorable responses. It should be mentioned that the clinical response to treatment is associated with manifestations of autoimmunity, including leukoderma, suggesting that CTLA-4 is important for maintaining peripheral tolerance to antigens.29 These and other molecules will continue to be studied in order to obtain an effective antitumor therapy with limited toxicity, and so improve the quality of life of patients affected by this aggressive malignant neoplasm.

In view of the immunogenic characteristics of melanoma, the development of antitumor vaccines continues to be a challenge. In fact, a vaccine has been developed that contains 6 melanoma-associated peptides, which are derived from the MAGE, MART-1/Melan A, gp100, and tyrosinase proteins. Toxicities associated with immunization include fatigue, headache, myalgia, arthralgia, and nausea. Other types of toxicities were of the autoimmune type, and included elevated rheumatoid factor (10%), treatment-associated leukoderma (10%), and antinuclear antibody elevations.30

The characteristics of the inductive and effective immune response present in melanoma-associated leukoderma lesions, as well as the selective destruction of pigmented cells in vitiligo, are the points on which further investigation will focus. In theory, therapy involving transfer of immunoglobulins from patients with vitiligo and administration to patients with melanoma would be possible. Self-transfer may also actually induce an antitumor immune response due to the induction of cross reactivity.31 It may even be that the serum of patients with generalized or universal vitiligo could have a more potent antimelanoma effect than that of patients with focal or segmentary vitiligo, and so this is an area of opportunity within the field of immuno-oncology.

**Ethical Responsibilities**

**Protection of human and animal subjects.** The authors declare that no tests were carried out in humans or animals for the purpose of this study.

**Confidentiality of data.** The authors declare that patient data do not appear in this article.

**Right to privacy and informed consent.** The authors obtained the informed consent of patients and/or subjects mentioned in this article. The informed consent form is located in the archives of the corresponding author.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**


gp-100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother. 2011;60:249–60.


